About the Company
We do not have any company description for Evolus, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $EOLS News
Evolus, Inc. (EOLS)
April 17, 2024--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the Aesthetic Surgery Journal has ...
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
Evolus, Inc. (Nasdaq: EOLS) announced today the pricing of its underwritten offering of 3,554,000 shares of its common stock at a underwritten offering price of $14.07 per share, which is equal to ...
Evolus Poised for Growth: Surpassing Q4 Expectations and Accelerating Profitability
Begin your TipRanks Premium journey today. Evolus (EOLS) Company Description: Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and ...
Evolus, Inc. (NASDAQ:EOLS) is favoured by institutional owners who hold 57% of the company
Given the large stake in the stock by institutions, Evolus' stock price might be vulnerable to their trading decisions 53% of the business is held by the top 10 shareholders Insiders have been ...
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra-Strength" 40U Formulation of Jeuveau®
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the Aesthetic Surgery Journal has published the ...
Evolus Stock (NASDAQ:EOLS), Analyst Ratings, Price Targets, Predictions
There is no last downgrade for Evolus.
Evolus Reports Pricing Of $50 Mln Underwritten Offering Of Common Stock
(RTTNews) - Monday, Evolus, Inc. (EOLS) announced the pricing of the underwritten offering of 3,554,000 shares of its common stock at $14.07 per share, matching the closing price on Friday ...
11 Best Small Cap Pharma Stocks to Invest In
A handful of such stocks that stand out are Collegium Pharmaceutical, Inc. (NASDAQ:COLL) and Evolus, Inc. (NASDAQ:EOLS).
Evolus Inc.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Evolus, Inc. (NASDAQ:EOLS) is favoured by institutional owners who hold 57% of the company
Given the large stake in the stock by institutions, Evolus' stock price might be vulnerable to their trading decisions 53% of the business is held by the top 10 shareholders Insiders have been ...
Loading the latest forecasts...